nodes	percent_of_prediction	percent_of_DWPC	metapath
Isoprenaline—CYP1A1—Dacarbazine—pancreatic cancer	0.142	0.405	CbGbCtD
Isoprenaline—CYP1A1—Tamoxifen—pancreatic cancer	0.113	0.322	CbGbCtD
Isoprenaline—CYP1A1—Erlotinib—pancreatic cancer	0.0964	0.274	CbGbCtD
Isoprenaline—Tachyarrhythmia—Epirubicin—pancreatic cancer	0.00426	0.0537	CcSEcCtD
Isoprenaline—Tachyarrhythmia—Doxorubicin—pancreatic cancer	0.00394	0.0497	CcSEcCtD
Isoprenaline—Pulmonary oedema—Sunitinib—pancreatic cancer	0.0018	0.0227	CcSEcCtD
Isoprenaline—Pulmonary oedema—Gemcitabine—pancreatic cancer	0.00145	0.0182	CcSEcCtD
Isoprenaline—Angina pectoris—Tamoxifen—pancreatic cancer	0.00144	0.0182	CcSEcCtD
Isoprenaline—Sweating—Tamoxifen—pancreatic cancer	0.00127	0.016	CcSEcCtD
Isoprenaline—Cardiac arrest—Irinotecan—pancreatic cancer	0.00115	0.0145	CcSEcCtD
Isoprenaline—Cardiac arrest—Fluorouracil—pancreatic cancer	0.0011	0.0139	CcSEcCtD
Isoprenaline—Flushing—Tamoxifen—pancreatic cancer	0.0011	0.0139	CcSEcCtD
Isoprenaline—Arrhythmia—Tamoxifen—pancreatic cancer	0.00106	0.0134	CcSEcCtD
Isoprenaline—Ventricular arrhythmia—Epirubicin—pancreatic cancer	0.00105	0.0132	CcSEcCtD
Isoprenaline—Arrhythmia—Erlotinib—pancreatic cancer	0.00105	0.0132	CcSEcCtD
Isoprenaline—Pulmonary oedema—Docetaxel—pancreatic cancer	0.00103	0.0129	CcSEcCtD
Isoprenaline—Angina pectoris—Irinotecan—pancreatic cancer	0.00102	0.0129	CcSEcCtD
Isoprenaline—Bronchospasm—Gemcitabine—pancreatic cancer	0.001	0.0126	CcSEcCtD
Isoprenaline—Angina pectoris—Fluorouracil—pancreatic cancer	0.000976	0.0123	CcSEcCtD
Isoprenaline—Ventricular arrhythmia—Doxorubicin—pancreatic cancer	0.000972	0.0123	CcSEcCtD
Isoprenaline—Flushing—Sunitinib—pancreatic cancer	0.000943	0.0119	CcSEcCtD
Isoprenaline—Arrhythmia—Sunitinib—pancreatic cancer	0.000908	0.0115	CcSEcCtD
Isoprenaline—Sweating—Irinotecan—pancreatic cancer	0.000894	0.0113	CcSEcCtD
Isoprenaline—Hypertension—Tamoxifen—pancreatic cancer	0.000892	0.0112	CcSEcCtD
Isoprenaline—Sweating—Gemcitabine—pancreatic cancer	0.000871	0.011	CcSEcCtD
Isoprenaline—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.000815	0.0103	CcSEcCtD
Isoprenaline—Flushing—Irinotecan—pancreatic cancer	0.000777	0.0098	CcSEcCtD
Isoprenaline—Convulsion—Sunitinib—pancreatic cancer	0.000767	0.00967	CcSEcCtD
Isoprenaline—Hypertension—Sunitinib—pancreatic cancer	0.000764	0.00963	CcSEcCtD
Isoprenaline—Insomnia—Tamoxifen—pancreatic cancer	0.000763	0.00962	CcSEcCtD
Isoprenaline—Insomnia—Erlotinib—pancreatic cancer	0.000755	0.00952	CcSEcCtD
Isoprenaline—Dyspnoea—Tamoxifen—pancreatic cancer	0.000752	0.00948	CcSEcCtD
Isoprenaline—Arrhythmia—Irinotecan—pancreatic cancer	0.000748	0.00943	CcSEcCtD
Isoprenaline—Dyspnoea—Erlotinib—pancreatic cancer	0.000744	0.00938	CcSEcCtD
Isoprenaline—Arrhythmia—Gemcitabine—pancreatic cancer	0.000729	0.00919	CcSEcCtD
Isoprenaline—Arrhythmia—Fluorouracil—pancreatic cancer	0.000716	0.00903	CcSEcCtD
Isoprenaline—Bronchospasm—Docetaxel—pancreatic cancer	0.000711	0.00897	CcSEcCtD
Isoprenaline—Angina pectoris—Docetaxel—pancreatic cancer	0.000704	0.00888	CcSEcCtD
Isoprenaline—Pulmonary oedema—Epirubicin—pancreatic cancer	0.000692	0.00873	CcSEcCtD
Isoprenaline—Vision blurred—Fluorouracil—pancreatic cancer	0.000658	0.0083	CcSEcCtD
Isoprenaline—Vertigo—Irinotecan—pancreatic cancer	0.000655	0.00826	CcSEcCtD
Isoprenaline—Insomnia—Sunitinib—pancreatic cancer	0.000653	0.00824	CcSEcCtD
Isoprenaline—Dyspnoea—Sunitinib—pancreatic cancer	0.000644	0.00812	CcSEcCtD
Isoprenaline—Pulmonary oedema—Doxorubicin—pancreatic cancer	0.00064	0.00807	CcSEcCtD
Isoprenaline—Hypertension—Irinotecan—pancreatic cancer	0.000629	0.00794	CcSEcCtD
Isoprenaline—Hypertension—Gemcitabine—pancreatic cancer	0.000613	0.00773	CcSEcCtD
Isoprenaline—Asthenia—Tamoxifen—pancreatic cancer	0.000605	0.00763	CcSEcCtD
Isoprenaline—Convulsion—Fluorouracil—pancreatic cancer	0.000605	0.00763	CcSEcCtD
Isoprenaline—Asthenia—Erlotinib—pancreatic cancer	0.000599	0.00755	CcSEcCtD
Isoprenaline—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000575	0.00725	CcSEcCtD
Isoprenaline—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00056	0.00706	CcSEcCtD
Isoprenaline—Dizziness—Tamoxifen—pancreatic cancer	0.000558	0.00703	CcSEcCtD
Isoprenaline—Tachycardia—Fluorouracil—pancreatic cancer	0.000556	0.00701	CcSEcCtD
Isoprenaline—Hypotension—Irinotecan—pancreatic cancer	0.000556	0.00701	CcSEcCtD
Isoprenaline—Dizziness—Erlotinib—pancreatic cancer	0.000552	0.00696	CcSEcCtD
Isoprenaline—Hypotension—Gemcitabine—pancreatic cancer	0.000541	0.00683	CcSEcCtD
Isoprenaline—Insomnia—Irinotecan—pancreatic cancer	0.000538	0.00679	CcSEcCtD
Isoprenaline—Flushing—Docetaxel—pancreatic cancer	0.000537	0.00677	CcSEcCtD
Isoprenaline—Cardiac arrest—Epirubicin—pancreatic cancer	0.000537	0.00677	CcSEcCtD
Isoprenaline—Hypotension—Fluorouracil—pancreatic cancer	0.000532	0.00671	CcSEcCtD
Isoprenaline—Dyspnoea—Irinotecan—pancreatic cancer	0.00053	0.00669	CcSEcCtD
Isoprenaline—Headache—Tamoxifen—pancreatic cancer	0.000528	0.00666	CcSEcCtD
Isoprenaline—Insomnia—Gemcitabine—pancreatic cancer	0.000524	0.00661	CcSEcCtD
Isoprenaline—Headache—Erlotinib—pancreatic cancer	0.000523	0.00659	CcSEcCtD
Isoprenaline—Asthenia—Sunitinib—pancreatic cancer	0.000518	0.00653	CcSEcCtD
Isoprenaline—Arrhythmia—Docetaxel—pancreatic cancer	0.000517	0.00652	CcSEcCtD
Isoprenaline—Dyspnoea—Gemcitabine—pancreatic cancer	0.000517	0.00652	CcSEcCtD
Isoprenaline—Insomnia—Fluorouracil—pancreatic cancer	0.000515	0.0065	CcSEcCtD
Isoprenaline—Dyspnoea—Fluorouracil—pancreatic cancer	0.000508	0.00641	CcSEcCtD
Isoprenaline—Nausea—Tamoxifen—pancreatic cancer	0.000501	0.00632	CcSEcCtD
Isoprenaline—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000497	0.00626	CcSEcCtD
Isoprenaline—Nausea—Erlotinib—pancreatic cancer	0.000496	0.00625	CcSEcCtD
Isoprenaline—Dizziness—Sunitinib—pancreatic cancer	0.000478	0.00602	CcSEcCtD
Isoprenaline—Angina pectoris—Epirubicin—pancreatic cancer	0.000475	0.00599	CcSEcCtD
Isoprenaline—Headache—Sunitinib—pancreatic cancer	0.000452	0.00571	CcSEcCtD
Isoprenaline—Palpitations—Docetaxel—pancreatic cancer	0.000445	0.00562	CcSEcCtD
Isoprenaline—Angina pectoris—Doxorubicin—pancreatic cancer	0.00044	0.00554	CcSEcCtD
Isoprenaline—Convulsion—Docetaxel—pancreatic cancer	0.000437	0.00551	CcSEcCtD
Isoprenaline—Hypertension—Docetaxel—pancreatic cancer	0.000435	0.00549	CcSEcCtD
Isoprenaline—Nausea—Sunitinib—pancreatic cancer	0.000429	0.00541	CcSEcCtD
Isoprenaline—Asthenia—Irinotecan—pancreatic cancer	0.000427	0.00538	CcSEcCtD
Isoprenaline—Sweating—Epirubicin—pancreatic cancer	0.000417	0.00526	CcSEcCtD
Isoprenaline—Asthenia—Gemcitabine—pancreatic cancer	0.000416	0.00524	CcSEcCtD
Isoprenaline—Tachycardia—Docetaxel—pancreatic cancer	0.000401	0.00506	CcSEcCtD
Isoprenaline—Dizziness—Irinotecan—pancreatic cancer	0.000393	0.00496	CcSEcCtD
Isoprenaline—Sweating—Doxorubicin—pancreatic cancer	0.000386	0.00487	CcSEcCtD
Isoprenaline—Hypotension—Docetaxel—pancreatic cancer	0.000384	0.00485	CcSEcCtD
Isoprenaline—Dizziness—Fluorouracil—pancreatic cancer	0.000377	0.00475	CcSEcCtD
Isoprenaline—Headache—Irinotecan—pancreatic cancer	0.000373	0.0047	CcSEcCtD
Isoprenaline—Insomnia—Docetaxel—pancreatic cancer	0.000372	0.00469	CcSEcCtD
Isoprenaline—Dyspnoea—Docetaxel—pancreatic cancer	0.000367	0.00462	CcSEcCtD
Isoprenaline—Headache—Gemcitabine—pancreatic cancer	0.000363	0.00458	CcSEcCtD
Isoprenaline—Flushing—Epirubicin—pancreatic cancer	0.000362	0.00457	CcSEcCtD
Isoprenaline—Headache—Fluorouracil—pancreatic cancer	0.000357	0.0045	CcSEcCtD
Isoprenaline—Nausea—Irinotecan—pancreatic cancer	0.000353	0.00446	CcSEcCtD
Isoprenaline—Arrhythmia—Epirubicin—pancreatic cancer	0.000349	0.0044	CcSEcCtD
Isoprenaline—Nausea—Gemcitabine—pancreatic cancer	0.000344	0.00434	CcSEcCtD
Isoprenaline—Nausea—Fluorouracil—pancreatic cancer	0.000338	0.00427	CcSEcCtD
Isoprenaline—Flushing—Doxorubicin—pancreatic cancer	0.000335	0.00423	CcSEcCtD
Isoprenaline—Tension—Epirubicin—pancreatic cancer	0.000334	0.00421	CcSEcCtD
Isoprenaline—Nervousness—Epirubicin—pancreatic cancer	0.00033	0.00416	CcSEcCtD
Isoprenaline—Arrhythmia—Doxorubicin—pancreatic cancer	0.000323	0.00407	CcSEcCtD
Isoprenaline—Vision blurred—Epirubicin—pancreatic cancer	0.00032	0.00404	CcSEcCtD
Isoprenaline—Tension—Doxorubicin—pancreatic cancer	0.000309	0.00389	CcSEcCtD
Isoprenaline—Nervousness—Doxorubicin—pancreatic cancer	0.000305	0.00385	CcSEcCtD
Isoprenaline—Vertigo—Epirubicin—pancreatic cancer	0.000305	0.00385	CcSEcCtD
Isoprenaline—Palpitations—Epirubicin—pancreatic cancer	0.0003	0.00379	CcSEcCtD
Isoprenaline—Vision blurred—Doxorubicin—pancreatic cancer	0.000296	0.00374	CcSEcCtD
Isoprenaline—Asthenia—Docetaxel—pancreatic cancer	0.000295	0.00372	CcSEcCtD
Isoprenaline—Convulsion—Epirubicin—pancreatic cancer	0.000294	0.00371	CcSEcCtD
Isoprenaline—Hypertension—Epirubicin—pancreatic cancer	0.000293	0.0037	CcSEcCtD
Isoprenaline—Vertigo—Doxorubicin—pancreatic cancer	0.000283	0.00356	CcSEcCtD
Isoprenaline—Palpitations—Doxorubicin—pancreatic cancer	0.000278	0.0035	CcSEcCtD
Isoprenaline—Convulsion—Doxorubicin—pancreatic cancer	0.000272	0.00344	CcSEcCtD
Isoprenaline—Dizziness—Docetaxel—pancreatic cancer	0.000272	0.00343	CcSEcCtD
Isoprenaline—Hypertension—Doxorubicin—pancreatic cancer	0.000271	0.00342	CcSEcCtD
Isoprenaline—Tachycardia—Epirubicin—pancreatic cancer	0.000271	0.00341	CcSEcCtD
Isoprenaline—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000268	0.00338	CcSEcCtD
Isoprenaline—Hypotension—Epirubicin—pancreatic cancer	0.000259	0.00327	CcSEcCtD
Isoprenaline—Headache—Docetaxel—pancreatic cancer	0.000258	0.00325	CcSEcCtD
Isoprenaline—Insomnia—Epirubicin—pancreatic cancer	0.000251	0.00316	CcSEcCtD
Isoprenaline—Tachycardia—Doxorubicin—pancreatic cancer	0.00025	0.00316	CcSEcCtD
Isoprenaline—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000248	0.00313	CcSEcCtD
Isoprenaline—Dyspnoea—Epirubicin—pancreatic cancer	0.000247	0.00312	CcSEcCtD
Isoprenaline—Nausea—Docetaxel—pancreatic cancer	0.000244	0.00308	CcSEcCtD
Isoprenaline—Hypotension—Doxorubicin—pancreatic cancer	0.00024	0.00302	CcSEcCtD
Isoprenaline—Insomnia—Doxorubicin—pancreatic cancer	0.000232	0.00293	CcSEcCtD
Isoprenaline—Dyspnoea—Doxorubicin—pancreatic cancer	0.000229	0.00289	CcSEcCtD
Isoprenaline—Asthenia—Epirubicin—pancreatic cancer	0.000199	0.00251	CcSEcCtD
Isoprenaline—Asthenia—Doxorubicin—pancreatic cancer	0.000184	0.00232	CcSEcCtD
Isoprenaline—Dizziness—Epirubicin—pancreatic cancer	0.000183	0.00231	CcSEcCtD
Isoprenaline—Headache—Epirubicin—pancreatic cancer	0.000174	0.00219	CcSEcCtD
Isoprenaline—Dizziness—Doxorubicin—pancreatic cancer	0.00017	0.00214	CcSEcCtD
Isoprenaline—Nausea—Epirubicin—pancreatic cancer	0.000165	0.00208	CcSEcCtD
Isoprenaline—Headache—Doxorubicin—pancreatic cancer	0.000161	0.00203	CcSEcCtD
Isoprenaline—Nausea—Doxorubicin—pancreatic cancer	0.000152	0.00192	CcSEcCtD
Isoprenaline—MAPK1—Innate Immune System—HRAS—pancreatic cancer	1.06e-05	1.86e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—AKT1—pancreatic cancer	1.06e-05	1.86e-05	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—CXCL8—pancreatic cancer	1.05e-05	1.85e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.05e-05	1.85e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—PIK3CA—pancreatic cancer	1.04e-05	1.84e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—HIF1A—pancreatic cancer	1.04e-05	1.84e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TSC2—pancreatic cancer	1.04e-05	1.83e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.04e-05	1.83e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—EGFR—pancreatic cancer	1.04e-05	1.83e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HES1—pancreatic cancer	1.04e-05	1.83e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—PIK3CB—pancreatic cancer	1.04e-05	1.82e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—AKT1—pancreatic cancer	1.04e-05	1.82e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—HRAS—pancreatic cancer	1.03e-05	1.81e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GCG—pancreatic cancer	1.03e-05	1.81e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—SRC—pancreatic cancer	1.03e-05	1.8e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—APOE—pancreatic cancer	1.02e-05	1.79e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.02e-05	1.79e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—HRAS—pancreatic cancer	1.02e-05	1.79e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—PIK3CB—pancreatic cancer	1.01e-05	1.78e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—SRC—pancreatic cancer	1.01e-05	1.78e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PIK3CB—pancreatic cancer	1.01e-05	1.77e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—VEGFA—pancreatic cancer	9.99e-06	1.76e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KDR—pancreatic cancer	9.99e-06	1.76e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PTGS2—pancreatic cancer	9.98e-06	1.76e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CXCL8—pancreatic cancer	9.97e-06	1.75e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—PIK3CB—pancreatic cancer	9.95e-06	1.75e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—HRAS—pancreatic cancer	9.91e-06	1.74e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—STAT3—pancreatic cancer	9.9e-06	1.74e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—NRAS—pancreatic cancer	9.87e-06	1.74e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—AKT1—pancreatic cancer	9.86e-06	1.73e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—VEGFA—pancreatic cancer	9.84e-06	1.73e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—KRAS—pancreatic cancer	9.83e-06	1.73e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—PIK3CA—pancreatic cancer	9.79e-06	1.72e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—PIK3CA—pancreatic cancer	9.78e-06	1.72e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	9.78e-06	1.72e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—STAT3—pancreatic cancer	9.75e-06	1.71e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CXCL8—pancreatic cancer	9.73e-06	1.71e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—NRAS—pancreatic cancer	9.72e-06	1.71e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—AKT1—pancreatic cancer	9.72e-06	1.71e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—CTNNB1—pancreatic cancer	9.67e-06	1.7e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—STK11—pancreatic cancer	9.67e-06	1.7e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—HRAS—pancreatic cancer	9.67e-06	1.7e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—GPCR downstream signaling—AKT1—pancreatic cancer	9.63e-06	1.69e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Metabolism—AKT1—pancreatic cancer	9.57e-06	1.68e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	9.56e-06	1.68e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CASP3—pancreatic cancer	9.54e-06	1.68e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NFKBIA—pancreatic cancer	9.5e-06	1.67e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—TP53—pancreatic cancer	9.47e-06	1.67e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—PTEN—pancreatic cancer	9.43e-06	1.66e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NOTCH1—pancreatic cancer	9.41e-06	1.66e-05	CbGpPWpGaD
Isoprenaline—ADRB3—GPCR downstream signaling—AKT1—pancreatic cancer	9.4e-06	1.65e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—PIK3CA—pancreatic cancer	9.34e-06	1.64e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—AKT1—pancreatic cancer	9.33e-06	1.64e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CASP3—pancreatic cancer	9.31e-06	1.64e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TERT—pancreatic cancer	9.31e-06	1.64e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CCND1—pancreatic cancer	9.29e-06	1.63e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CG—pancreatic cancer	9.2e-06	1.62e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—NRAS—pancreatic cancer	9.2e-06	1.62e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CTNNB1—pancreatic cancer	9.2e-06	1.62e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—MYC—pancreatic cancer	9.2e-06	1.62e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TGFB1—pancreatic cancer	9.17e-06	1.61e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TERT—pancreatic cancer	9.11e-06	1.6e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—AKT1—pancreatic cancer	9.11e-06	1.6e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—EGF—pancreatic cancer	9.1e-06	1.6e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.08e-06	1.6e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CCND1—pancreatic cancer	9.07e-06	1.59e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—HRAS—pancreatic cancer	9.06e-06	1.59e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—MYC—pancreatic cancer	9.06e-06	1.59e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—HRAS—pancreatic cancer	9.05e-06	1.59e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TGFB1—pancreatic cancer	9.04e-06	1.59e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—PIK3CA—pancreatic cancer	9.03e-06	1.59e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MMP9—pancreatic cancer	9.02e-06	1.59e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—EGFR—pancreatic cancer	8.99e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CTNNB1—pancreatic cancer	8.98e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—AKT1—pancreatic cancer	8.97e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—PTEN—pancreatic cancer	8.97e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CTNNB1—pancreatic cancer	8.93e-06	1.57e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	8.9e-06	1.57e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	8.88e-06	1.56e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—EGFR—pancreatic cancer	8.86e-06	1.56e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MMP9—pancreatic cancer	8.8e-06	1.55e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—PTEN—pancreatic cancer	8.75e-06	1.54e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—AKT1—pancreatic cancer	8.75e-06	1.54e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—SRC—pancreatic cancer	8.74e-06	1.54e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	8.71e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PTEN—pancreatic cancer	8.7e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—APOE—pancreatic cancer	8.69e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	8.69e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—AKT1—pancreatic cancer	8.54e-06	1.5e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KDR—pancreatic cancer	8.52e-06	1.5e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—APOE—pancreatic cancer	8.5e-06	1.5e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—KRAS—pancreatic cancer	8.5e-06	1.49e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—STAT3—pancreatic cancer	8.43e-06	1.48e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—NRAS—pancreatic cancer	8.41e-06	1.48e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—EGFR—pancreatic cancer	8.39e-06	1.47e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—KRAS—pancreatic cancer	8.37e-06	1.47e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—HRAS—pancreatic cancer	8.36e-06	1.47e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KDR—pancreatic cancer	8.33e-06	1.47e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—TYMS—pancreatic cancer	8.32e-06	1.46e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—SRC—pancreatic cancer	8.31e-06	1.46e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—SRC—pancreatic cancer	8.11e-06	1.43e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	8.1e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—VEGFA—pancreatic cancer	8.1e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CD—pancreatic cancer	8.09e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—SRC—pancreatic cancer	8.07e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	8.02e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—STAT3—pancreatic cancer	8.02e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—AKT1—pancreatic cancer	8e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—NRAS—pancreatic cancer	8e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—AKT1—pancreatic cancer	7.99e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	7.92e-06	1.39e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—KRAS—pancreatic cancer	7.92e-06	1.39e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—VEGFA—pancreatic cancer	7.9e-06	1.39e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	7.85e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	7.84e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	7.84e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—STAT3—pancreatic cancer	7.83e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—NRAS—pancreatic cancer	7.81e-06	1.37e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—PIK3CA—pancreatic cancer	7.81e-06	1.37e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—STAT3—pancreatic cancer	7.78e-06	1.37e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—NRAS—pancreatic cancer	7.76e-06	1.37e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EGF—pancreatic cancer	7.75e-06	1.36e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—PIK3CA—pancreatic cancer	7.69e-06	1.35e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	7.67e-06	1.35e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	7.67e-06	1.35e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—EGFR—pancreatic cancer	7.66e-06	1.35e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—AKT1—pancreatic cancer	7.63e-06	1.34e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EGF—pancreatic cancer	7.58e-06	1.33e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—PIK3CA—pancreatic cancer	7.56e-06	1.33e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TP53—pancreatic cancer	7.55e-06	1.33e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MYC—pancreatic cancer	7.45e-06	1.31e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TP53—pancreatic cancer	7.44e-06	1.31e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TGFB1—pancreatic cancer	7.43e-06	1.31e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—AKT1—pancreatic cancer	7.38e-06	1.3e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—EGFR—pancreatic cancer	7.29e-06	1.28e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—PIK3CA—pancreatic cancer	7.28e-06	1.28e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MYC—pancreatic cancer	7.27e-06	1.28e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TGFB1—pancreatic cancer	7.25e-06	1.28e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—KRAS—pancreatic cancer	7.24e-06	1.27e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MYC—pancreatic cancer	7.23e-06	1.27e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—HRAS—pancreatic cancer	7.22e-06	1.27e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—TGFB1—pancreatic cancer	7.21e-06	1.27e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	7.15e-06	1.26e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—HRAS—pancreatic cancer	7.11e-06	1.25e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—EGFR—pancreatic cancer	7.11e-06	1.25e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—EGFR—pancreatic cancer	7.07e-06	1.24e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CB—pancreatic cancer	7.05e-06	1.24e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	6.99e-06	1.23e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	6.9e-06	1.21e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—KRAS—pancreatic cancer	6.88e-06	1.21e-05	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.83e-06	1.2e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CXCL8—pancreatic cancer	6.78e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—APOE—pancreatic cancer	6.77e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	6.75e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	6.75e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—HRAS—pancreatic cancer	6.73e-06	1.18e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—KRAS—pancreatic cancer	6.72e-06	1.18e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—KRAS—pancreatic cancer	6.68e-06	1.18e-05	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.68e-06	1.18e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—PIK3CA—pancreatic cancer	6.65e-06	1.17e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	6.6e-06	1.16e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CASP3—pancreatic cancer	6.49e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.4e-06	1.13e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—AKT1—pancreatic cancer	6.38e-06	1.12e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—PIK3CA—pancreatic cancer	6.32e-06	1.11e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CCND1—pancreatic cancer	6.31e-06	1.11e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—AKT1—pancreatic cancer	6.28e-06	1.1e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CTNNB1—pancreatic cancer	6.25e-06	1.1e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.2e-06	1.09e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—AKT1—pancreatic cancer	6.18e-06	1.09e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—PIK3CA—pancreatic cancer	6.17e-06	1.09e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—HRAS—pancreatic cancer	6.15e-06	1.08e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PIK3CA—pancreatic cancer	6.14e-06	1.08e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MMP9—pancreatic cancer	6.13e-06	1.08e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TP53—pancreatic cancer	6.12e-06	1.08e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	6.11e-06	1.07e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PTEN—pancreatic cancer	6.09e-06	1.07e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	6.07e-06	1.07e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	6.01e-06	1.06e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TP53—pancreatic cancer	5.97e-06	1.05e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—AKT1—pancreatic cancer	5.95e-06	1.05e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PPARG—pancreatic cancer	5.89e-06	1.04e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	5.88e-06	1.03e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—HRAS—pancreatic cancer	5.85e-06	1.03e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	5.78e-06	1.02e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	5.74e-06	1.01e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—HRAS—pancreatic cancer	5.71e-06	1e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—HRAS—pancreatic cancer	5.68e-06	9.99e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SRC—pancreatic cancer	5.65e-06	9.94e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	5.65e-06	9.94e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	5.61e-06	9.87e-06	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	5.58e-06	9.81e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	5.53e-06	9.72e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—VEGFA—pancreatic cancer	5.5e-06	9.68e-06	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	5.46e-06	9.6e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—STAT3—pancreatic cancer	5.45e-06	9.59e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NRAS—pancreatic cancer	5.44e-06	9.56e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—AKT1—pancreatic cancer	5.43e-06	9.55e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	5.41e-06	9.51e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	5.38e-06	9.46e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	5.37e-06	9.44e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	5.33e-06	9.37e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	5.26e-06	9.26e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	5.22e-06	9.19e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	5.21e-06	9.17e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	5.19e-06	9.14e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—AKT1—pancreatic cancer	5.17e-06	9.09e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	5.11e-06	8.99e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	5.08e-06	8.94e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	5.07e-06	8.91e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MYC—pancreatic cancer	5.06e-06	8.91e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TGFB1—pancreatic cancer	5.05e-06	8.89e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—AKT1—pancreatic cancer	5.04e-06	8.87e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—AKT1—pancreatic cancer	5.02e-06	8.82e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	4.96e-06	8.72e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—EGFR—pancreatic cancer	4.95e-06	8.71e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SRC—pancreatic cancer	4.82e-06	8.47e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SRC—pancreatic cancer	4.71e-06	8.29e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	4.69e-06	8.25e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KRAS—pancreatic cancer	4.68e-06	8.23e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	4.68e-06	8.23e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	4.64e-06	8.17e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PTGS2—pancreatic cancer	4.64e-06	8.15e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	4.63e-06	8.15e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	4.59e-06	8.07e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	4.54e-06	7.99e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	4.53e-06	7.97e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MYC—pancreatic cancer	4.32e-06	7.59e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	4.31e-06	7.57e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CA—pancreatic cancer	4.3e-06	7.56e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MYC—pancreatic cancer	4.22e-06	7.43e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	4.22e-06	7.43e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	4.21e-06	7.41e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TP53—pancreatic cancer	4.16e-06	7.32e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	4.13e-06	7.26e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PTEN—pancreatic cancer	4.04e-06	7.11e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	3.99e-06	7.01e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—HRAS—pancreatic cancer	3.98e-06	7e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	3.9e-06	6.86e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	3.66e-06	6.44e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	3.58e-06	6.3e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TP53—pancreatic cancer	3.54e-06	6.23e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—AKT1—pancreatic cancer	3.51e-06	6.18e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TP53—pancreatic cancer	3.47e-06	6.1e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	3.39e-06	5.96e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	3.32e-06	5.83e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	2.99e-06	5.26e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	2.93e-06	5.15e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	2.85e-06	5.02e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—AKT1—pancreatic cancer	2.33e-06	4.1e-06	CbGpPWpGaD
